Skip to content

Pharmaceutical Crystallization Summit

Breaking Drug Development Bottlenecks via Enabling Technologies

October 14-15, 2021

  • Home
  • Program
    • Program for Live Attendance
    • Program for Virtual Attendance
  • Abstracts
    • Session 1: Smarter Solid Form & Pre-formulation Studies
    • Session 2: Particle Engineering & DS-DP Co-Processing
    • Session 3: Physical Property Based Crystallization Process Development
  • Keynote Speakers & Moderators
  • Venue
    • Chauncey Hotel & Conference Center
    • COVID-19 Safety Protocols
    • Destination Guide
  • Partners
    • Center for Pharma Crystallization
    • J-STAR Research, Inc.
    • Porton Pharma Solutions Ltd.
    • XtalPi
    • BlazeMetrics
    • Technobis Crystallization Systems
  • COVID-19 Prevention
    • Chauncey’s Health & Safety Plan
    • PCS COVID-19 Prevention

Session 1: Smarter Solid Form & Pre-formulation Studies

Moderator: Dr. Shanming Kuang, J-Star/Porton

Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264): A Solid-State Chemistry Perspective

Dr. Alfred Lee, Merck Research Laboratories

Read More

What Solid Form Should I Choose?

Ann Newman, Seventh Street Development Group

Read More

Understanding and Controlling the API Form/Powder Property Risks in Drug Substance and Product Processes

Dr. Shawn Yin, Bristol Myers Squibb

Read More

Absolute Structure Determination of API Molecules by MicroED analysis of Cocrystals formed based on Cocrystal Propensity Prediction Calculations

Drs. Chandler Greenwell (XtalPi), Harsh Shah (J-Star), and Jessica Bruhn (NIS)

Read More

Abstracts

  • Abstracts (15)
    • Session 1: Smarter Solid Form & Pre-formulation Studies (4)
    • Session 2: Particle Engineering & DS-DP Co-Processing (4)
    • Session 3: Physical Property Based Crystallization Process Development (4)
    • Session 4: Topical Panel Discussions (3)

© 2021 Pharmaceutical Crystallization Summit. All Rights Reserved.

Scroll To Top